Role of plasma PlGF, PDGF-AA, ANG-1, ANG-2, and the ANG-1/ANG-2 ratio as predictors of preeclampsia in a cohort of pregnant women

Machado, Jackeline de Souza Rangel; Machado, Michelle; Bertagnolli, Tawana Vicente; Martins, Luiz Augusto Beltramin; Freitas, Stella Felippe de; Ovídio, Paula P.; Sandrim, Valéria C.; Cardoso, Valtemar Fernandes; Bettiol, Heloísa; Barbieri, Marco Antônio; Cavalli, Ricardo Carvalho

doi:10.1016/j.preghy.2019.03.011

Cited by 8 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the result of this study was in agreement with Machado et al's study. 16 They performed a case-control study of pregnant women with gestational age of 20-25 weeks. They found that Ang-1 level, Ang-2 level and Ang-1/Ang-2 ratio were not different between pregnant women with PE and the healthy controls.…”

Section: Discussionmentioning

confidence: 99%

Serum Angiopoietin-1/Angiopoietin-2 at 16-18 Weeks of Gestation to Predict Preeclampsia

Phupong

Tanbirojn

Lertkhachonsuk

2021

J Health Sci Med Res

View full text Add to dashboard Cite

Objective: To determine whether serum angiopoietin-1/angiopoietin-2 ratio can predict preeclampsia in women at 16–18 weeks of gestation, or not.Material and Methods: This was a prospective observational study that was conducted in pregnant women with gestational age of 16-18 weeks. Serum angiopoietin-1 and angiopoietin-2 levels were acquired. The predictive values of these tests were calculated.Results: Data from 269 pregnant women were analyzed. Twenty-two cases developed preeclampsia, and five of these cases had early onset preeclampsia. When the angiopoietin-1/angiopoietin-2 ratio was above 6.2, the sensitivity, specificity, positive predictive value and negative predictive values to predict preeclampsia were 50.0%, 72.9%, 14.1% and 94.2%, respectively. When angiopoietin-1 was used to predict preeclampsia, the sensitivity, specificity, positive predictive value and negative predictive values were 59.1%, 65.2%, 13.1% and 94.7%, respectively. When angiopoietin-2 was used to predict preeclampsia, the sensitivity, specificity, positive predictive value and negative predictive values were 63.6%, 50.2%, 10.2% and 93.9%, respectively.Conclusion: This study demonstrated that serum angiopoietin-1/angiopoietin-2 ratio at 16-18 weeks of gestation was not effective in predicting preeclampsia. However, angiopoietin-2 may be used to predict preeclampsia.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Angiopoietin-1/Angiopoietin-2 at 16-18 Weeks of Gestation to Predict Preeclampsia

Phupong

Tanbirojn

Lertkhachonsuk

2021

J Health Sci Med Res

View full text Add to dashboard Cite

show abstract

“…For assessment regarding the efficiency of functional probes, the stability is key factor for proper functioning of nanomaterials. For this purpose, the volume of residual ANG in the supernatant solution was quantified via a BCA protein concentration by using standard method, and it was found that the grafting rate of ANG was equal to 63.9%, which is highly feasible for diagnosis of diseases like cancer. , However, when samples underwent phase changes or chemical reaction, they absorbed and emitted heat, and the glass transition temperature may have accordingly changed that was detected by DSC. The glass transition temperatures of ANG and FA-PLGA-NPs were found to be 29.84 and 34.16 °C, respectively, while ANG/FA-PLGA-NPs showed two peaks in the graph with the glass transition temperatures of 33.14 °C (ANG) and 36.89 °C (FA-PLGA).…”

Section: Resultsmentioning

confidence: 99%

Interpreting the Therapeutic Efficiency of Multifunctional Hybrid Nanostructure against Glioblastoma

You

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Glioblastoma is considered the most fatal malignant brain tumor that starts from the central nervous system (CNS), where the blood−brain barrier (BBB) remains the biggest challenge for active targeting of drugs in malignant brain tumor. Thereby, we have designed a paclitaxel PTX@ANG/FA-NPs hybrid novel nanodrug delivery system that can overcome the clinical BBB. The structural and morphological characterization of PTX@ ANG/FA-NPs confirmed successful synthesis of nanomicelles with the size range of about 160 to 170 nm. The overall repressive effect of PTX@ANG/FA-NPs on human glioblastoma U251 cells was 1.2-times that of PTX alone. In vitro cellular uptake assay also demonstrated that the dual-targeted nanoparticles (NPs) were more easily taken up by glioblastoma U251 cells. Although the antiglioblastoma activity was confirmed by cell migration assay, apoptosis assay, and cellular uptake assay, the absorption was studied by in vivo fluorescence imaging and brain distribution. The synthesized PTX@ANG/FA-NPs probe significantly inhibited the migration of U251 within the cells and promoted the apoptosis process. Moreover, the RhB@ ANG/FA-NPs and PTX@ANG/FA-NPs showed higher accumulating potential at sites of tumor BBB disruption. The novel nanodrug delivery system mediated enhanced distribution of drugs at the targeted site for therapeutics efficacies against glioblastomas across the BBB.

show abstract

“…Since most of the cases of PE occur after 25 weeks of gestation, we focused on the period of 20–25 weeks of gestation in order to maximize the chance to find predictive biomarkers to monitor the pregnancy. In this context, several candidates for circulating biomarkers have been studied, such as pregnancy-associated plasma protein-A (PAPP-A), C-reactive protein (CRP), interleukin-1β (IL-1β), antiangiogenic molecules, homocysteine, oxidative stress markers, and vasoactive peptides (Levine et al, 2004 ; D'antonio et al, 2013 ; Maged et al, 2017 ; Rocha-Penha et al, 2017 ; Lind Malte et al, 2018 ; Sandrim et al, 2018a , b ; Machado et al, 2019 ). However, most of these biomarkers showed poor to moderate predictive value for PE.…”

Section: Discussionmentioning

confidence: 99%

Circulating MicroRNAs in the Second Trimester From Pregnant Women Who Subsequently Developed Preeclampsia: Potential Candidates as Predictive Biomarkers and Pathway Analysis for Target Genes of miR-204-5p

et al. 2021

View full text Add to dashboard Cite

MicroRNAs (miRNAs) play an important role in the pathophysiology of preeclampsia (PE). However, the expression of circulating miRNAs was not analyzed in the second trimester of pregnancy, a period of major relevance to identify predictive biomarkers for PE. Therefore, we examined the expression profiles of 84 circulating miRNAs using a PCR array in plasma collected between 20 and 25 weeks of gestation from pregnant women, who subsequently developed PE and those who remained healthy during pregnancy, randomly selected from a prospective cohort. Overall, 23 miRNAs had a fold change > 2.0 and were considered to be upregulated in plasma from pregnant women who subsequently developed PE, even before the onset of clinical symptoms of PE. However, only miR-204-5p was statistically significant (P = 0.0082). Experimentally validated interactions for the target genes of miR-204-5p extracted from miRTarBase were used in the gene set functional enrichment analysis to identify Reactome pathways. The network connecting the 37 target genes for miR-204-5p revealed pathways of known pathophysiological relevance during the early development of PE and included key genes related to PE, such as BDNF, MMP-9, MALAT1, TGFBR2, and SIRT1. We further depicted downstream targets of SIRT1 that are related to the vascular endothelial function or implicated in the pathophysiology of PE, namely, FOXO1, NFκB, HIF-1α, NOS3, and PPAR-γ. Our novel findings provide for circulating miRNAs upregulated in the second trimester on plasma from pregnant women who subsequently developed PE that is potentially related to the early development of PE, which may guide further studies focused on the validation of potential predictive biomarkers in PE.

show abstract

Role of plasma PlGF, PDGF-AA, ANG-1, ANG-2, and the ANG-1/ANG-2 ratio as predictors of preeclampsia in a cohort of pregnant women

Cited by 8 publications

References 26 publications

Serum Angiopoietin-1/Angiopoietin-2 at 16-18 Weeks of Gestation to Predict Preeclampsia

Serum Angiopoietin-1/Angiopoietin-2 at 16-18 Weeks of Gestation to Predict Preeclampsia

Interpreting the Therapeutic Efficiency of Multifunctional Hybrid Nanostructure against Glioblastoma

Circulating MicroRNAs in the Second Trimester From Pregnant Women Who Subsequently Developed Preeclampsia: Potential Candidates as Predictive Biomarkers and Pathway Analysis for Target Genes of miR-204-5p

Contact Info

Product

Resources

About